Stay updated with breaking news from Ablative Solutions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...
Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.
This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),
Welcome to the MassDevice Fast Five medtech news podcast. Here’s what you need to know for today, December 20, 2023.
Ablative Solutions announced today that its TARGET BP I pivotal trial evaluating its Peregrine System kit met its primary endpoint.